Peripheral Nervous System Drugs Quizlet

Option D: Denervation super-sensitivity includes proliferation of receptors, loss of mechanisms for transmitter removal, and increased post-junctional responsiveness, making it a comprehensive phenomenon that enhances neuronal responsiveness following denervation.

Option A: Proliferation of receptors is a component of denervation super-sensitivity but does not encompass the entire concept, which includes additional mechanisms.

Option B: Loss of mechanism for transmitter removal contributes to denervation super-sensitivity but is not the sole factor, as increased receptor sensitivity and proliferation also play critical roles.

Option C: Increased post-junctional responsiveness is a significant aspect of denervation super-sensitivity, yet it alone does not capture the full scope of the phenomenon, which includes receptor proliferation and transmitter removal mechanisms.

Takeaways: Denervation super-sensitivity involves multiple mechanisms, including receptor proliferation, loss of transmitter removal, and increased post-junctional responsiveness, highlighting the complexity of neuronal adaptations following injury, as detailed in this resource on synaptic plasticity.

Option D: Pilocarpine is a direct-acting cholinomimetic that is lipid-soluble and effectively used in the treatment of glaucoma by increasing aqueous humor outflow, thereby reducing intraocular pressure. Its ability to penetrate the blood-brain barrier enhances its therapeutic profile in certain conditions.

Option A: Acetylcholine is not lipid-soluble and is rapidly hydrolyzed by acetylcholinesterase, limiting its use in glaucoma treatment.

Option B: Bethanechol is a direct-acting cholinomimetic but is not lipid-soluble and primarily used for urinary retention rather than glaucoma.

Option C: Physostigmine is an acetylcholinesterase inhibitor, not a direct-acting cholinomimetic, and while it can be used in glaucoma, it does not fit the lipid-soluble criterion as well as pilocarpine.

Takeaways: Pilocarpine, a lipid-soluble direct-acting cholinomimetic, is commonly used in glaucoma treatment due to its ability to enhance aqueous humor outflow, requiring patient education regarding its use and potential side effects.

Option B: Isoprenaline is a non-selective beta-adrenergic agonist that directly stimulates both β1 and β2 adrenoceptors, leading to increased heart rate and bronchodilation. This dual action makes it effective in treating conditions like asthma and bradycardia.

Option A: Noradrenaline primarily stimulates α1 and β1 adrenoceptors, with minimal effect on β2 adrenoceptors, thus it does not fulfill the requirement of being a direct stimulant of both β1 and β2 receptors.

Option C: Salbutamol selectively stimulates β2 adrenoceptors, primarily used for bronchodilation in asthma, but it does not act on β1 adrenoceptors, making it unsuitable for this question.

Option D: Amphetamine primarily acts as a central nervous system stimulant and increases the release of norepinephrine and dopamine, but it does not directly stimulate β1 and β2 adrenoceptors.

Takeaways: Understanding the specific receptor activity of adrenergic agonists is crucial in pharmacology, as isoprenaline's dual action on both β1 and β2 adrenoceptors highlights its therapeutic role in conditions requiring both cardiac stimulation and bronchodilation, which requires knowledge of adrenergic receptor pharmacology for effective treatment planning.

Option C: Propranolol is not indicated for the treatment of heart block, as it can exacerbate the condition by further decreasing heart rate and conduction through the AV node. This beta-blocker is primarily used for conditions where it can reduce heart workload and anxiety symptoms.

Option A: Propranolol effectively treats hypertension by blocking beta-adrenergic receptors, leading to decreased heart rate and cardiac output, which lowers blood pressure.

Option B: Propranolol is beneficial in managing anxiety, particularly performance anxiety, due to its ability to mitigate physical symptoms such as tachycardia and tremors.

Option D: Propranolol is also used to treat angina of effort by reducing myocardial oxygen demand through decreased heart rate and contractility.

Takeaways: Propranolol is contraindicated in heart block due to its potential to worsen the condition, while it effectively manages hypertension, anxiety, and angina of effort; understanding these indications requires knowledge of beta-blocker pharmacology.

D. All of the above definitively reduces transmitter release by blocking nerve terminal calcium channels, a mechanism shared by all listed agents. Botulinum toxin inhibits acetylcholine release at the neuromuscular junction, while both ß-bungarotoxin and ω-conotoxin also interfere with calcium channel function, leading to reduced neurotransmitter release.

Option A: Botulinum toxin effectively blocks acetylcholine release by preventing calcium influx at the nerve terminal, confirming its role in reducing transmitter release.

Option B: ß-bungarotoxin acts on presynaptic calcium channels, inhibiting neurotransmitter release, thus contributing to the overall effect of reducing transmitter release.

Option C: ω-conotoxin specifically blocks calcium channels, leading to decreased neurotransmitter release, aligning with the mechanism described in the question.

Takeaways: Understanding that agents like botulinum toxin, ß-bungarotoxin, and ω-conotoxin all reduce transmitter release by blocking calcium channels highlights the importance of calcium in neurotransmitter release mechanisms, which requires knowledge of synaptic transmission and pharmacological interventions.

Option D: Atenolol is primarily eliminated unchanged by renal excretion, making it unique among beta-blockers in this regard. This characteristic is crucial for understanding dosing adjustments in patients with renal impairment, as accumulation can lead to adverse effects. Atenolol's pharmacokinetics necessitate careful monitoring in such populations.

Option A: Propranolol undergoes extensive hepatic metabolism, with only a small fraction excreted unchanged in the urine. This significantly affects its dosing and monitoring in patients with liver dysfunction rather than renal issues.

Option B: Metoprolol is also primarily metabolized by the liver, with renal excretion playing a minor role. Its pharmacokinetic profile requires adjustments based on hepatic function rather than renal clearance.

Option C: Alprenolol is metabolized by the liver and does not have significant renal excretion of unchanged drug. Its elimination pathway does not align with the question's criteria regarding renal clearance.

Takeaways: Atenolol's elimination primarily through renal excretion highlights the importance of monitoring renal function in patients receiving beta-blockers, especially in those with renal impairment, as it requires adjustments in dosing based on renal function.

Option D: Epinephrine causes vasoconstriction, which can lead to vascular ischemia in digits. In delicate surgeries, particularly in areas like fingers, the use of epinephrine can compromise blood flow, risking tissue viability and healing. Therefore, local anesthetics without epinephrine are preferred to avoid potential ischemic complications during digit reattachment.

Option A: Epinephrine does not cause increased blood loss; rather, it typically reduces blood loss by causing vasoconstriction. This option misrepresents the physiological effects of epinephrine during surgical procedures.

Option B: Epinephrine does not cause swelling of tissues; it actually constricts blood vessels, which can reduce swelling. This option incorrectly attributes a physiological response to epinephrine that is not accurate.

Option C: Epinephrine is not contraindicated in emergency surgery; it is often used to manage bleeding. This option misstates the role of epinephrine in surgical contexts, particularly in emergencies.

Takeaways: Understanding the effects of epinephrine, particularly its vasoconstrictive properties, is crucial in surgical settings to prevent complications such as vascular ischemia in digits, which requires careful consideration when administering local anesthetics during procedures like digit reattachment. For further details on this topic, see vasoconstriction and its implications in surgery.

Option B: Adrenaline effectively produces both bronchodilation and raises blood pressure due to its action as a non-selective adrenergic agonist. It stimulates beta-2 receptors in the lungs, leading to bronchodilation, while also stimulating alpha and beta-1 receptors, resulting in increased heart rate and vascular resistance, thereby elevating blood pressure.

Option A: Atropine primarily acts as an anticholinergic agent, which can increase heart rate but does not provide bronchodilation or raise blood pressure effectively in emergency situations.

Option C: Isoproterenol is a non-selective beta-adrenergic agonist that causes bronchodilation but does not significantly raise blood pressure, as it can lead to vasodilation and decreased vascular resistance.

Option D: Noradrenaline primarily acts on alpha-1 adrenergic receptors to raise blood pressure but does not provide bronchodilation, making it unsuitable for this dual requirement.

Takeaways: Adrenaline is crucial in emergency settings for its dual action of bronchodilation and blood pressure elevation, which is essential for managing severe asthma or anaphylaxis; understanding its pharmacological effects is vital for effective patient care in emergencies, as outlined in clinical guidelines for the use of adrenaline.

Option B: Yohimbine acts as an antagonist at alpha-2 adrenergic receptors, leading to increased sympathetic outflow and enhanced norepinephrine release. This pharmacological action is utilized in treating erectile dysfunction and as a potential aid in weight loss by promoting lipolysis. Understanding the receptor specificity of yohimbine is crucial for its clinical applications.

Option A: Yohimbine does not primarily act as an antagonist at alpha-1 receptors; its main action is on alpha-2 receptors, which are involved in inhibiting norepinephrine release.

Option C: Yohimbine specifically antagonizes alpha-2 receptors and does not have a significant antagonistic effect on alpha-1 receptors, making this option inaccurate.

Option D: There are indeed specific receptors that yohimbine antagonizes, particularly alpha-2 adrenergic receptors, thus this option misrepresents the pharmacological profile of yohimbine.

Takeaways: Yohimbine is an antagonist of alpha-2 adrenergic receptors, which plays a role in increasing norepinephrine release and has implications in treating conditions like erectile dysfunction; understanding this mechanism is essential for effective patient management and requires further exploration of adrenergic receptor functions in pharmacology.

Option D: Beta-adrenergic antagonists can mask the symptoms of hypoglycemia in diabetic patients by inhibiting the adrenergic response that typically signals low blood sugar levels, such as tachycardia and tremors. This can lead to unrecognized hypoglycemia, increasing the risk of severe complications.

Option A: Beta-adrenergic agonists stimulate adrenergic receptors, which can actually increase blood glucose levels rather than mask hypoglycemic reactions.

Option B: Alpha-adrenergic antagonists do not have a significant role in masking hypoglycemic symptoms and primarily affect peripheral vascular resistance and blood pressure.

Option C: Alpha-adrenergic agonists can cause vasoconstriction and do not directly influence the perception of hypoglycemia, thus not masking its symptoms.

Takeaways: Understanding the effects of beta-adrenergic antagonists on hypoglycemia is crucial for managing diabetic patients, as these agents can mask symptoms and lead to unrecognized low blood sugar levels, necessitating careful monitoring and patient education on hypoglycemia management.

Option A: Pancuronium is a neuromuscular blocker that exhibits significant antivagal properties, making it effective in reducing vagal tone during surgical procedures. This characteristic is particularly beneficial in managing bradycardia and other vagally mediated responses, enhancing its utility in anesthesia.

Option B: Vecuronium does not possess notable antivagal effects, primarily functioning as a neuromuscular blocker without significant influence on vagal tone.

Option C: Atracurium lacks prominent antivagal action and is primarily used for its neuromuscular blocking properties without affecting vagal responses.

Option D: Gallamine triethiodide is an older neuromuscular blocker that does not exhibit significant antivagal activity, focusing instead on muscle relaxation without influencing vagal tone.

Takeaways: Pancuronium's unique antivagal action makes it a valuable neuromuscular blocker in clinical settings, particularly during anesthesia, where managing vagal tone is crucial; understanding these properties requires knowledge of neuromuscular blockers and their pharmacological effects.

Option B: Salivary glands are extremely sensitive to the action of atropine, which is an anticholinergic agent that inhibits the secretion of saliva. This results in dry mouth, a common side effect of atropine, highlighting its significant impact on salivary gland function.

Option A: Gastric glands do not exhibit the same level of sensitivity to atropine as salivary glands, as atropine primarily affects secretions in the mouth rather than gastric acid production.

Option C: The urinary bladder muscle is not as directly influenced by atropine; while it can affect bladder function, the primary sensitivity lies with salivary glands.

Option D: The heart does respond to atropine, particularly in terms of heart rate modulation, but it is not the organ most sensitive to its effects compared to the salivary glands.

Takeaways: Understanding the pharmacological effects of atropine, particularly its significant impact on the salivary glands, is crucial for managing side effects in patients. This requires knowledge of anticholinergic medications and their effects to ensure appropriate patient care.

Option B: Ganglion cervicale sup. (superior cervical ganglion) is the correct source of sympathetic fibers to the ciliary ganglion, which innervates the eye's sphincter pupillae and ciliary muscles, facilitating pupil dilation and accommodation. This connection is crucial for understanding autonomic control of ocular functions.

Option A: None is correct does not apply, as the superior cervical ganglion is indeed the origin of sympathetic fibers to the ciliary ganglion.

Option C: Ganglion sphenoidale is not a recognized anatomical structure associated with sympathetic innervation to the ciliary ganglion, making this option factually inaccurate.

Option D: Ganglion cervicale inf. does not provide sympathetic fibers to the ciliary ganglion; instead, it primarily relates to the innervation of the heart and other structures in the neck.

Takeaways: Understanding the origin of sympathetic fibers, specifically from the superior cervical ganglion to the ciliary ganglion is essential for grasping the autonomic nervous system's role in ocular physiology.

Option D: Increases blood flow to the injection area. Adrenaline, when combined with local anesthetics, actually causes vasoconstriction, which reduces blood flow to the area of injection, thereby prolonging the anesthetic effect and minimizing systemic absorption.

Option A: Reduces the absorption of local anesthetic. Adrenaline decreases the absorption of local anesthetics into the bloodstream by causing vasoconstriction, which helps maintain localized effects.

Option B: Increases the duration of its local anesthetic activity. The vasoconstrictive properties of adrenaline prolong the duration of action of local anesthetics by limiting their systemic absorption and maintaining higher concentrations at the site of action.

Option C: Decreases the toxicity of the local anesthetic. By reducing systemic absorption, adrenaline can help decrease the potential toxicity of local anesthetics, making this statement accurate.

Takeaways: Adrenaline's role in local anesthetic formulations includes reducing absorption and increasing duration of action, while also decreasing toxicity; it does not increase blood flow to the injection area, as it induces vasoconstriction, which is crucial for effective anesthesia management and requires understanding the pharmacological interactions of local anesthetics.

Option C: By a nonexocytotic process accurately describes how tyramine induces the release of noradrenaline. Tyramine facilitates the release of noradrenaline from adrenergic nerve endings through a mechanism that does not involve the typical exocytotic pathway, allowing for a more direct release into the synaptic cleft.

Option A: By depolarizing the axonal membrane does not apply here, as tyramine's action does not primarily rely on membrane depolarization to induce neurotransmitter release.

Option B: By mobilizing Ca2+ is misleading; while calcium is crucial for neurotransmitter release, tyramine's mechanism is distinct and does not depend on calcium mobilization in the same way as traditional exocytosis.

Option D: Only in the presence of MAO inhibitors is inaccurate; while MAO inhibitors can enhance tyramine's effects, tyramine can induce noradrenaline release independently of these inhibitors, as it acts through a different mechanism.

Takeaways: Tyramine induces noradrenaline release through a nonexocytotic process, which is a unique mechanism distinct from traditional neurotransmitter release pathways. Understanding this mechanism is essential for managing dietary restrictions in patients on MAO inhibitors.

Option D: The physician recommends a drug that blocks 5α-reductase in the prostate, which is effective in treating benign prostatic hyperplasia (BPH). 5α-reductase inhibitors, such as finasteride or dutasteride, reduce prostate size and improve urinary symptoms. Therefore, 'None of the above' is the correct choice as no other options listed are appropriate for this condition.

Option A: Atropine is an anticholinergic agent that can cause urinary retention, making it unsuitable for treating urinary hesitancy associated with BPH.

Option B: Clonidine is an alpha-2 adrenergic agonist primarily used for hypertension and does not address the underlying issue of prostate enlargement or urinary hesitancy.

Option C: Hydralazine is a vasodilator used for hypertension and does not have a role in managing urinary symptoms related to BPH.

Takeaways: Understanding the role of 5α-reductase inhibitors in managing benign prostatic hyperplasia is crucial, as these medications effectively reduce prostate size and improve urinary flow, requiring patient education on the mechanism and benefits of these medications for optimal treatment outcomes.